Accelerated Pharma (Accelerated Pharma) Debt-to-Equity : -0.70 (As of Mar. 2017)

View and export this data going back to 2016. Start your Free Trial

What is Accelerated Pharma Debt-to-Equity?

Accelerated Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $3.69 Mil. Accelerated Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2017 was $1.23 Mil. Accelerated Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2017 was $-6.99 Mil. Accelerated Pharma's debt to equity for the quarter that ended in Mar. 2017 was -0.70.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Accelerated Pharma's Debt-to-Equity or its related term are showing as below:

ACCP's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

Accelerated Pharma Debt-to-Equity Historical Data

The historical data trend for Accelerated Pharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerated Pharma Debt-to-Equity Chart

Accelerated Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Debt-to-Equity

-2.09

-0.64

-0.72

Accelerated Pharma Quarterly Data
	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Debt-to-Equity	Get a 7-Day Free Trial			N/A	-0.73	-0.76	-0.72	-0.70

Competitive Comparison of Accelerated Pharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Accelerated Pharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accelerated Pharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Accelerated Pharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Accelerated Pharma's Debt-to-Equity falls into.

Accelerated Pharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Accelerated Pharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2016 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.38	+	1.211)	/	-6.403
	=	-0.72

Accelerated Pharma's Debt to Equity Ratio for the quarter that ended in Mar. 2017 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.685	+	1.229)	/	-6.991
	=	-0.70

Accelerated Pharma (NAS:ACCP) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Accelerated Pharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Accelerated Pharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerated Pharma (Accelerated Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Accelerated Pharma Inc (NAS:ACCP) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Accelerated Pharma Inc, is a Delaware corporation organized on May 12, 2014. It is a biopharmaceutical company focused on utilizing its genomic technology to enhance the development and commercialization of pharmaceutical products. Its lead product candidate is Picoplatin, a new generation platinum-based cancer therapy that has the potential for use in different formulations, as a single agent or in combination with other anti-cancer agents, to treat multiple cancer indications.

Accelerated Pharma (Accelerated Pharma) Headlines

No Headlines